Population-wide screening for albuminuria followed by treatment with conventional CKD therapy and SGLT2 inhibitors reduced the burden of kidney failure requiring KRT across all age groups compared with status quo case finding with conventional CKD therapy alone (Figure 1). This evidence concerns the gene SLC5A2 and chronic kidney disease.